Tristel ups divi as profits climb

12th Oct 2009 07:17

The continuing struggle to keep infections such as Clostridium difficile out of hospitals helped disinfectant supplier Tristel post a rise in turnover and profits in the year to June 30.Tristel, whose products are based on chlorine dioxide chemistry, said revenues climbed to £6.8m from £6m over the same period the previous year, while pre-tax profits rose to £1.3m from £1.2m.It will lift the final dividend to 1.295p from 1.165p, taking the full-year dividend to 1.7p, compared with 1.55p over the previous year.Tristel also announced that it had licensed its chlorine dioxide chemistry to US bleach maker the Clorox Company. The partnership with the S&P 500-listed company is Tristel's second attempt to enter the US market. It abandoned earlier efforts due to regulatory hurdles.Tristel said it expects to remain well insulated from the public spending cuts that are expected to be implemented in the UK and Europe. 'There are well publicised performance targets for the control of hospital acquired infections and we cannot imagine a scenario in which they will be abandoned,' the firm said.